Neo-Islets
Type 1 Diabetes / Insulin-dependent Diabetes
Pre-clinicalActive
Key Facts
Indication
Type 1 Diabetes / Insulin-dependent Diabetes
Phase
Pre-clinical
Status
Active
Company
About SymbioCellTech
SymbioCellTech is a private, preclinical-stage biotech based in San Diego, founded in 2018, focused on curing diabetes without immunosuppression. Its patented 'Neo-Islet' platform creates hybrid cell clusters that engraft and provide immune-isolated insulin secretion. The company has demonstrated promising preclinical proof-of-concept, including in diabetic dogs, and is targeting human clinical trials. It is a 2024 winner of the American Diabetes Association's Innovation Challenge Award.
View full company profile